Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors.
The management of peritoneal and hepatic metastases from gastrointestinal stromal tumors is a challenging clinical problem. Currently available systemic therapeutic agents have very limited activity in this particular disease. Patients with disease confined to a single organ/region are therefore managed either by surgery or regional therapy e.g. intraperitoneal therapy or hepatic arterial chemoembolization, whereas those with multiple sites of involvement should be enrolled on experimental trials of new agents.
Patel
S R
SR
Department of Melanoma-Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. spatel@notes.mdacc.tmc.edu
Benjamin
R S
RS
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008297:Male; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D011379:Prognosis; D012509:Sarcoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D015996:Survival Rate